SCHEMBL3392608

SCHEMBL3392608

COc1ccc(C(=O)Nc2sc(Nc3ccnc(Cl)c3)nc2C(N)=O)cc1

nearest known ligand 0.70

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 19/20 0.70
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3396631 0.89 TNIK (0.71) TNIKLMNATP53POLBMAPT
SCHEMBL3397358 0.89 TNIK (0.71) TNIKLMNATP53POLBMAPT
SCHEMBL3397654 0.89 TNIK (0.70) TNIKLMNATP53POLBMAPT
SCHEMBL2367268 0.86 TNIK (0.68) TNIKLMNATP53POLBMAPT
SCHEMBL3398128 0.86 TNIK (0.77) TNIKLMNATP53POLBMAPT
SCHEMBL16700223 0.85 TNIK (0.81) TNIKTP53MAPT
SCHEMBL13224859 0.84 TNIK (0.72) TNIKLMNATP53POLBMAPT
Hydrochloric Acid SCHEMBL3397582 0.83 TNIK (0.71) TNIKLMNATP53POLBMAPT
SCHEMBL2367192 0.83 TNIK (0.78) TNIKLMNATP53POLBMAPT
SCHEMBL16710247 0.82 TNIK (1.00) TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364149-B1 TNIK INHIBITOR AND THE USE NAT CANCER CT (JP) 2014-05-07 EP disclosed
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216795-A1 TNIK INHIBITOR AND THE USE TNIK, TNNI3K, TNK1 TNIK 1/4885LMNA 4362/4885TP53 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.